Compare $RCEL vs $SPRY | Chartloom

Compare

$RCEL vs $SPRY

AVITA Medical Inc · ARS Pharmaceuticals Inc

RCEL

AVITA Medical Inc

SPRY

ARS Pharmaceuticals Inc

Compare $RCEL vs $SPRY

Comparing AVITA Medical Inc and ARS Pharmaceuticals Inc

RCELAVITA Medical Inc

SPRYARS Pharmaceuticals Inc

RCELAVITA Medical Inc

Market cap

$407M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

4.05x

Rev growth (TTM)

1.0%

YTD performance

280.7%

52W performance

139.7%

FCF yield

-6.2%

SPRYARS Pharmaceuticals Inc

Market cap

$420M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.81x

Rev growth (TTM)

4.1%

YTD performance

-63.2%

52W performance

-61.9%

FCF yield

-46.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

RCEL

SPRY

Detailed metrics comparison

RCEL

AVITA Medical Inc

SPRY

ARS Pharmaceuticals Inc

Market Cap

RCEL$407M

SPRY$420M

Enterprise Value

RCEL$444M

SPRY$509M

Price

RCEL$13.21

SPRY$4.23

P/E Ratio

RCELN/A

SPRYN/A

P/S Ratio

RCEL5.38x

SPRY3.59x

EV/Sales

RCEL5.87x

SPRY4.35x

EV/EBITDA

RCEL0.00x

SPRY0.00x

P/B Ratio

RCEL87.44x

SPRY32.35x

P/FCF Ratio

RCELN/A

SPRYN/A

EV/FCF

RCEL-17.54x

SPRY-2.59x

PEG Ratio

RCELN/A

SPRYN/A

Forward P/E (NTM)

RCELN/A

SPRYN/A

Forward P/S (NTM)

RCEL4.05x

SPRY2.81x

Revenue (TTM)

RCEL$76M

SPRY$117M

Revenue Growth (YoY)

RCEL1.0%

SPRY4.1%

Forward Rev Growth

RCEL20.3%

SPRY46.9%

Gross Margin (TTM)

RCEL82.1%

SPRY71.4%

Operating Margin (TTM)

RCEL0.0%

SPRY0.0%

EBITDA Margin (TTM)

RCEL-41.9%

SPRY-183.6%

Net Margin (TTM)

RCEL-57.0%

SPRY-184.2%

FCF Margin (TTM)

RCEL-33.5%

SPRY-168.1%

Net Income (TTM)

RCEL$-43M

SPRY$-215M

FCF (TTM)

RCEL$-25M

SPRY$-197M

EPS (TTM)

RCEL-$1.40

SPRY-$2.17

ROE (TTM)

RCEL-33790.0%

SPRY-25667.0%

ROA (TTM)

RCEL-7853.0%

SPRY-6963.0%

ROIC (TTM)

RCEL-10295.0%

SPRY-11943.0%

Cash

RCEL$9M

SPRY$8M

Debt

RCEL$47M

SPRY$97M

Net Cash/Debt

RCEL$-38M

SPRY$-89M

Current Ratio (TTM)

RCEL0.41x

SPRY3.48x

Quick Ratio (TTM)

RCEL0.31x

SPRY3.13x

Debt/Equity (TTM)

RCEL9.39x

SPRY7.73x

Debt/Assets (TTM)

RCEL0.0%

SPRY0.0%

Interest Coverage (TTM)

RCELN/A

SPRYN/A

Net Debt/EBITDA (TTM)

RCEL0.00x

SPRY0.00x

Beta

RCEL2.07

SPRY0.92

52W Performance

RCEL139.7%

SPRY-61.9%

YTD Performance

RCEL280.7%

SPRY-63.2%

% from 52W High

RCEL-3.7%

SPRY-67.8%

% from 52W Low

RCEL310.2%

SPRY6.1%

Asset Turnover (TTM)

RCEL1.38x

SPRY0.38x

FCF Yield (TTM)

RCEL-6.2%

SPRY-46.8%

Earnings Yield (TTM)

RCEL-10.6%

SPRY-51.3%

Dividend Yield (TTM)

RCELN/A

SPRYN/A

Rule of 40

RCEL-32.5

SPRY-164.1

EV/GP/RG

RCEL0.22

SPRY0.16

Ticker research

View RCEL research View SPRY research

Metric	RCEL AVITA Medical Inc	SPRY ARS Pharmaceuticals Inc
Market & Valuation
Market Cap	$407M	$420M
Enterprise Value	$444M	$509M
Price	$13.21	$4.23
P/E Ratio	N/A	N/A
P/S Ratio	5.38x	3.59x
EV/Sales	5.87x	4.35x
EV/EBITDA	0.00x	0.00x
P/B Ratio	87.44x	32.35x
P/FCF Ratio	N/A	N/A
EV/FCF	-17.54x	-2.59x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	4.05x	2.81x
Revenue & Growth
Revenue (TTM)	$76M	$117M
Revenue Growth (YoY)	1.0%	4.1%
Forward Rev Growth	20.3%	46.9%
Profitability
Gross Margin (TTM)	82.1%	71.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-41.9%	-183.6%
Net Margin (TTM)	-57.0%	-184.2%
FCF Margin (TTM)	-33.5%	-168.1%
Net Income (TTM)	$-43M	$-215M
FCF (TTM)	$-25M	$-197M
EPS (TTM)	-$1.40	-$2.17
ROE (TTM)	-33790.0%	-25667.0%
ROA (TTM)	-7853.0%	-6963.0%
ROIC (TTM)	-10295.0%	-11943.0%
Financial Health
Cash	$9M	$8M
Debt	$47M	$97M
Net Cash/Debt	$-38M	$-89M
Current Ratio (TTM)	0.41x	3.48x
Quick Ratio (TTM)	0.31x	3.13x
Debt/Equity (TTM)	9.39x	7.73x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.07	0.92
52W Performance	139.7%	-61.9%
YTD Performance	280.7%	-63.2%
% from 52W High	-3.7%	-67.8%
% from 52W Low	310.2%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	1.38x	0.38x
FCF Yield (TTM)	-6.2%	-46.8%
Earnings Yield (TTM)	-10.6%	-51.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-32.5	-164.1
EV/GP/RG	0.22	0.16
Ticker research	View RCEL research	View SPRY research

Valuation

P/S Ratio

SPRY

3.59x

RCEL

5.38x

EV/FCF

RCEL

-17.54x

SPRY

-2.59x

Growth & revenue

Revenue Growth TTM

SPRY

4.1%

RCEL

1.0%

Forward Revenue Growth

SPRY

46.9%

RCEL

20.3%

Profitability & performance

Gross Margin

RCEL

82.1%

SPRY

71.4%

ROE

SPRY

-25667.0%

RCEL

-33790.0%

FCF Yield %

RCEL

-6.2%

SPRY

-46.8%

52-Week Performance

RCEL

139.7%

SPRY

-61.9%

Detailed metrics comparison

RCEL

AVITA Medical Inc

SPRY

ARS Pharmaceuticals Inc

Market Cap

RCEL$407M

SPRY$420M

Enterprise Value

RCEL$444M

SPRY$509M

Price

RCEL$13.21

SPRY$4.23

P/E Ratio

RCELN/A

SPRYN/A

P/S Ratio

RCEL5.38x

SPRY3.59x

EV/Sales

RCEL5.87x

SPRY4.35x

EV/EBITDA

RCEL0.00x

SPRY0.00x

P/B Ratio

RCEL87.44x

SPRY32.35x

P/FCF Ratio

RCELN/A

SPRYN/A

EV/FCF

RCEL-17.54x

SPRY-2.59x

PEG Ratio

RCELN/A

SPRYN/A

Forward P/E (NTM)

RCELN/A

SPRYN/A

Forward P/S (NTM)

RCEL4.05x

SPRY2.81x

Revenue (TTM)

RCEL$76M

SPRY$117M

Revenue Growth (YoY)

RCEL1.0%

SPRY4.1%

Forward Rev Growth

RCEL20.3%

SPRY46.9%

Gross Margin (TTM)

RCEL82.1%

SPRY71.4%

Operating Margin (TTM)

RCEL0.0%

SPRY0.0%

EBITDA Margin (TTM)

RCEL-41.9%

SPRY-183.6%

Net Margin (TTM)

RCEL-57.0%

SPRY-184.2%

FCF Margin (TTM)

RCEL-33.5%

SPRY-168.1%

Net Income (TTM)

RCEL$-43M

SPRY$-215M

FCF (TTM)

RCEL$-25M

SPRY$-197M

EPS (TTM)

RCEL-$1.40

SPRY-$2.17

ROE (TTM)

RCEL-33790.0%

SPRY-25667.0%

ROA (TTM)

RCEL-7853.0%

SPRY-6963.0%

ROIC (TTM)

RCEL-10295.0%

SPRY-11943.0%

Cash

RCEL$9M

SPRY$8M

Debt

RCEL$47M

SPRY$97M

Net Cash/Debt

RCEL$-38M

SPRY$-89M

Current Ratio (TTM)

RCEL0.41x

SPRY3.48x

Quick Ratio (TTM)

RCEL0.31x

SPRY3.13x

Debt/Equity (TTM)

RCEL9.39x

SPRY7.73x

Debt/Assets (TTM)

RCEL0.0%

SPRY0.0%

Interest Coverage (TTM)

RCELN/A

SPRYN/A

Net Debt/EBITDA (TTM)

RCEL0.00x

SPRY0.00x

Beta

RCEL2.07

SPRY0.92

52W Performance

RCEL139.7%

SPRY-61.9%

YTD Performance

RCEL280.7%

SPRY-63.2%

% from 52W High

RCEL-3.7%

SPRY-67.8%

% from 52W Low

RCEL310.2%

SPRY6.1%

Asset Turnover (TTM)

RCEL1.38x

SPRY0.38x

FCF Yield (TTM)

RCEL-6.2%

SPRY-46.8%

Earnings Yield (TTM)

RCEL-10.6%

SPRY-51.3%

Dividend Yield (TTM)

RCELN/A

SPRYN/A

Rule of 40

RCEL-32.5

SPRY-164.1

EV/GP/RG

RCEL0.22

SPRY0.16

Ticker research

View RCEL research View SPRY research

Metric	RCEL AVITA Medical Inc	SPRY ARS Pharmaceuticals Inc
Market & Valuation
Market Cap	$407M	$420M
Enterprise Value	$444M	$509M
Price	$13.21	$4.23
P/E Ratio	N/A	N/A
P/S Ratio	5.38x	3.59x
EV/Sales	5.87x	4.35x
EV/EBITDA	0.00x	0.00x
P/B Ratio	87.44x	32.35x
P/FCF Ratio	N/A	N/A
EV/FCF	-17.54x	-2.59x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	4.05x	2.81x
Revenue & Growth
Revenue (TTM)	$76M	$117M
Revenue Growth (YoY)	1.0%	4.1%
Forward Rev Growth	20.3%	46.9%
Profitability
Gross Margin (TTM)	82.1%	71.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-41.9%	-183.6%
Net Margin (TTM)	-57.0%	-184.2%
FCF Margin (TTM)	-33.5%	-168.1%
Net Income (TTM)	$-43M	$-215M
FCF (TTM)	$-25M	$-197M
EPS (TTM)	-$1.40	-$2.17
ROE (TTM)	-33790.0%	-25667.0%
ROA (TTM)	-7853.0%	-6963.0%
ROIC (TTM)	-10295.0%	-11943.0%
Financial Health
Cash	$9M	$8M
Debt	$47M	$97M
Net Cash/Debt	$-38M	$-89M
Current Ratio (TTM)	0.41x	3.48x
Quick Ratio (TTM)	0.31x	3.13x
Debt/Equity (TTM)	9.39x	7.73x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.07	0.92
52W Performance	139.7%	-61.9%
YTD Performance	280.7%	-63.2%
% from 52W High	-3.7%	-67.8%
% from 52W Low	310.2%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	1.38x	0.38x
FCF Yield (TTM)	-6.2%	-46.8%
Earnings Yield (TTM)	-10.6%	-51.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-32.5	-164.1
EV/GP/RG	0.22	0.16
Ticker research	View RCEL research	View SPRY research